WC
PRVL

Wexford Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Wexford Capital’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,963
Closed -$437K – 408
2020
Q4 		$437K Sell
18,963
-19,000
-50% -$241K 0.07% 133
2020
Q3 		$386K Buy
+37,963
New +$509K 0.1% 96

Wexford Capital's PRVL Position: Q1 2021 in Review

Wexford Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 18,963 shares — an estimated $437K sold.

Wexford Capital first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $437K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Wexford Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 18,963 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $437K.
  • Wexford Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Wexford Capital's Prevail Therapeutics Inc. Common Stock position peaked at $437K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.